United Therapeutics (UTHR) News Today $364.33 +3.62 (+1.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 14,800 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Premier Fund Managers LtdPremier Fund Managers Ltd acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,800 shares of the biotechnology comNovember 20 at 6:28 AM | marketbeat.comSeizert Capital Partners LLC Has $13.94 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)Seizert Capital Partners LLC lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 59.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,906 shares of the biotechnology companNovember 17, 2024 | marketbeat.comEmpowered Funds LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)Empowered Funds LLC reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 51.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,229 shares of the biotechnology companyNovember 16, 2024 | marketbeat.comCornercap Investment Counsel Inc. Has $726,000 Position in United Therapeutics Co. (NASDAQ:UTHR)Cornercap Investment Counsel Inc. cut its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 61.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,027 shares of the biotechnology company's stock after selling 3,257 shares during the quarterNovember 16, 2024 | marketbeat.comUnited Therapeutics: Competitive Advantages At Such Cheap Multiples Scream BuyNovember 15, 2024 | seekingalpha.comUnited Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles LoomNovember 15, 2024 | seekingalpha.comKBC Group NV Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)KBC Group NV decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,886 shares of the biotechnology company's stock aNovember 15, 2024 | marketbeat.comPlato Investment Management Ltd Sells 1,414 Shares of United Therapeutics Co. (NASDAQ:UTHR)Plato Investment Management Ltd decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 35.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,594 shares ofNovember 15, 2024 | marketbeat.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 15,000 Shares of StockNovember 15, 2024 | americanbankingnews.comVictory Capital Management Inc. Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Victory Capital Management Inc. lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 21.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 186,819 shares of the biotechnology company's stock after purchasing an additional 33,5November 15, 2024 | marketbeat.comEntropy Technologies LP Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Entropy Technologies LP lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 43.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,683 shares of the biotechnology company's stock afterNovember 15, 2024 | marketbeat.comUnited Therapeutics: One To Believe In Despite Competitive ThreatsNovember 14, 2024 | seekingalpha.comUnited Therapeutics: One To Believe In Despite Competitive ThreatsNovember 14, 2024 | seekingalpha.comChase Investment Counsel Corp Takes $492,000 Position in United Therapeutics Co. (NASDAQ:UTHR)Chase Investment Counsel Corp bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,375 shares of the biotechnologyNovember 13, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Nilda Mesa Sells 224 SharesNovember 13, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D lessened its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 15,439 shares of the biotechnology company's stock after selling 1,464 shares during thNovember 12, 2024 | marketbeat.comPrincipal Financial Group Inc. Sells 44,683 Shares of United Therapeutics Co. (NASDAQ:UTHR)Principal Financial Group Inc. trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 28.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,473 shares of the biotechnoloNovember 12, 2024 | marketbeat.comWeil Company Inc. Decreases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Weil Company Inc. cut its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,803 shares of the biotechnology company's stNovember 11, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Los Angeles Capital Management LLCLos Angeles Capital Management LLC lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 90,567 shares of the biotechnNovember 11, 2024 | marketbeat.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells $6,021,600.00 in StockNovember 11, 2024 | americanbankingnews.comFiera Capital Corp Buys Shares of 1,444 United Therapeutics Co. (NASDAQ:UTHR)Fiera Capital Corp purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,444 shares of the biotechnology company's sNovember 11, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issuedNovember 10, 2024 | marketbeat.comAssetmark Inc. Has $150.49 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Assetmark Inc. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 419,957 shares of the biotechnology company's stock after purchasing an additional 152,2November 9, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $6,021,600.00 in StockNovember 9, 2024 | insidertrades.comGalvin Gaustad & Stein LLC Invests $8.96 Million in United Therapeutics Co. (NASDAQ:UTHR)Galvin Gaustad & Stein LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 25,007 shares of the biotechnology company's stock, valued at approximately $8,961,000. Galvin GaustadNovember 9, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 15,000 SharesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 15,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.November 8, 2024 | marketbeat.comPhilip James Wealth Mangement LLC Invests $475,000 in United Therapeutics Co. (NASDAQ:UTHR)Philip James Wealth Mangement LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,325 shares of the biotechnology company's stock, valued at approximately $475,000.November 8, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Summit Global InvestmentsSummit Global Investments decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,999 shares of the biotechnology companNovember 8, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Hits New 1-Year High - What's Next?United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High - Should You Buy?November 7, 2024 | marketbeat.com1,846 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Hanseatic Management Services Inc.Hanseatic Management Services Inc. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,846 shares of the biotechnology company's stock, valued at approximately $662,000. Other insNovember 7, 2024 | marketbeat.comFinancial Enhancement Group LLC Makes New $6.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)Financial Enhancement Group LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 18,616 shares of the biotechnology company's stock, valued at approximately $6,671,00November 7, 2024 | marketbeat.comAmalgamated Bank Trims Holdings in United Therapeutics Co. (NASDAQ:UTHR)Amalgamated Bank lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 15.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,565 shares of the biotechnology company's stock after selling 3,841 shNovember 7, 2024 | marketbeat.comNational Pension Service Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)National Pension Service lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 38.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 113,742 shares of the biotechnology company's stock after purchasNovember 7, 2024 | marketbeat.com1,331 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by HMS Capital Management LLCHMS Capital Management LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,331 shares of the biotechnology company's stock, valued at approximately $477,November 6, 2024 | marketbeat.comUnited Therapeutics Corporation to Present at the UBS Global Healthcare ConferenceNovember 5, 2024 | businesswire.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by AlphaCentric Advisors LLCAlphaCentric Advisors LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,250 shares of the biNovember 5, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Buys 6,839 Shares of United Therapeutics Co. (NASDAQ:UTHR)Robeco Institutional Asset Management B.V. increased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 196,019 shares of the biotechnology company's stNovember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in StockNovember 5, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 14,700 SharesNovember 5, 2024 | insidertrades.comEmerald Advisers LLC Takes $692,000 Position in United Therapeutics Co. (NASDAQ:UTHR)Emerald Advisers LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,932 shares of the biotechnology company's stock, valued at approximately $6November 4, 2024 | marketbeat.comNew York State Teachers Retirement System Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)New York State Teachers Retirement System increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,411 shares of the biotechnology companyNovember 2, 2024 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | insidermonkey.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs GroupThe Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday.November 1, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Reaches New 52-Week High Following Analyst UpgradeUnited Therapeutics (NASDAQ:UTHR) Hits New 52-Week High on Analyst UpgradeNovember 1, 2024 | marketbeat.comQ3 2024 United Therapeutics Corp Earnings CallNovember 1, 2024 | uk.finance.yahoo.comOppenheimer Sticks to Their Buy Rating for United Therapeutics (UTHR)October 31, 2024 | markets.businessinsider.comJefferies Remains a Buy on United Therapeutics (UTHR)October 31, 2024 | markets.businessinsider.comLADENBURG THALM/SH SH Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) StockLADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday.October 31, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by AustralianSuper Pty LtdAustralianSuper Pty Ltd raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,029 shares of the biotechnology company's stock afterOctober 31, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPSUnited Therapeutics (NASDAQ:UTHR - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the company posted $5.38 EPS. The company's revenue was up 22.9% compared to the same quarter last year.October 31, 2024 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.570.45▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼1310▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News BPMC News BHVN News BBIO News PRGO News BHC News ARWR News ALNY News BIIB News INCY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
